225 related articles for article (PubMed ID: 37422615)
1. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
3. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
[TBL] [Abstract][Full Text] [Related]
7. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
8. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma.
Pender A; Davis EJ; Chauhan D; Messiou C; Al-Muderis O; Thway K; Fisher C; Zaidi S; Miah A; Judson I; van der Graaf W; Keedy VL; Benson C; Jones RL
Med Oncol; 2018 Aug; 35(10):131. PubMed ID: 30128716
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
[TBL] [Abstract][Full Text] [Related]
12. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.
Luo Z; Zhang X; Peng W; Wu X; Wang H; Yu H; Wang J; Chang J; Hong X
Medicine (Baltimore); 2015 Oct; 94(43):e1777. PubMed ID: 26512574
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
Oncologist; 2012; 17(3):321. PubMed ID: 22363068
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Lee EM; Rha SY; Lee J; Park KH; Ahn JH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
[TBL] [Abstract][Full Text] [Related]
16. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Hensley ML
Curr Opin Oncol; 2010 Jul; 22(4):356-61. PubMed ID: 20520541
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Bay JO; Ray-Coquard I; Fayette J; Leyvraz S; Cherix S; Piperno-Neumann S; Chevreau C; Isambert N; Brain E; Emile G; Le Cesne A; Cioffi A; Kwiatkowski F; Coindre JM; Bui NB; Peyrade F; Penel N; Blay JY;
Int J Cancer; 2006 Aug; 119(3):706-11. PubMed ID: 16496406
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
20. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
Pautier P; Floquet A; Penel N; Piperno-Neumann S; Isambert N; Rey A; Bompas E; Cioffi A; Delcambre C; Cupissol D; Collin F; Blay JY; Jimenez M; Duffaud F
Oncologist; 2012; 17(9):1213-20. PubMed ID: 22907974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
